Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major

This study has been terminated.
Information provided by:
Office of Rare Diseases (ORD) Identifier:
First received: December 6, 2000
Last updated: June 23, 2005
Last verified: October 2003


I. Determine the safety and efficacy of azacitidine and phenylbutyrate in treatment of patients with thalassemia major.

Condition Intervention Phase
Thalassemia Major
Drug: azacitidine
Drug: phenylbutyrate
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 24
Study Start Date: November 2000
Detailed Description:

PROTOCOL OUTLINE: Patients receive azacitidine IV continuously on days 1-4 and oral phenylbutyrate three times a day on days 14-42. Bone marrow needle aspiration is performed on days 6, 14, and 42 to assess disease response to treatment. If no response on day 42, a second course of azacitidine and phenylbutyrate begins 7 days later.

Patients are followed weekly for 3 months and then monthly thereafter.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


--Disease Characteristics--

Diagnosis of thalassemia major Progressive disease defined as: Increasing transfusion requirement or difficulty in maintenance of hemoglobin levels greater than 7 g/dL as a consequence of autologous or allogeneic antibodies OR Increasing extramedullary hematopoiesis causing compression phenomena OR Disease with complications of iron overload despite traditional transfusion and iron chelation therapy (e.g., heart failure, decreased cardiac ejection fraction, endocrinopathy, or evidence of progressive liver dysfunction)

Standard transfusion therapy or iron chelation therapy must be contraindicated

--Prior/Concurrent Therapy--

See Disease Characteristics

--Patient Characteristics--

Performance status: ECOG 0-2

Life expectancy: Greater than 10 days Not moribund

Hematopoietic: See Disease Characteristics

Hepatic: See Disease Characteristics AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN (unless due to hemolysis or Gilbert's disease) Albumin at least 3 g/dL No severe concurrent hepatic disease

Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No severe concurrent renal disease

Cardiovascular: See Disease Characteristics No New York Heart Association class III or IV

Other: Not pregnant or nursing No severe concurrent metabolic disease No severe sepsis or septic shock No concurrent altered mental status or seizure disorder No concurrent myelodysplastic syndrome or leukemia

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00007072

United States, Maryland
Clinical Hematology Branch
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Chair: Griffin Platt Rodgers National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  More Information Identifier: NCT00007072     History of Changes
Other Study ID Numbers: 199/15578
Study First Received: December 6, 2000
Last Updated: June 23, 2005

Keywords provided by Office of Rare Diseases (ORD):
genetic diseases and dysmorphic syndromes
hematologic disorders
rare disease
thalassemia major

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
4-phenylbutyric acid
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors processed this record on April 28, 2017